Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy

  • Technology appraisal guidance
  • TA1156
  • Published: 
Following the committee meeting on 20 November 2025 further work is being conducted and the expected publication date has been amended.

This page was last updated: